Vast majority show seropositivity four months after the second COVID-19 vaccine dose
FRIDAY, Aug. 20, 2021 (HealthDay News) — The seropositivity rate among patients with cancer remains high four months after the second dose of the COVID-19 vaccine, according to a research letter published online Aug. 11 in JAMA Oncology.
Noa Eliakim-Raz, M.D., from the Rabin Medical Center in Petah Tikva, Israel, and colleagues assessed the antispike (anti-S) immunoglobulin (Ig)G antibody response to the messenger RNA vaccine (BioNTech-Pfizer) in 95 patients with cancer versus 66 controls approximately four months after the second vaccine dose.
The researchers found that after a median of 123 days from the second vaccination, 87 percent of patients and 100 percent of the controls were seropositive for anti-S IgG antibodies. In patients with cancer, the median titer levels were significantly lower than those in the control group (417 versus 1,220 arbitrary units per milliliter). Median IgG titers varied 3.6-fold by tumor type and 8.8-fold by anticancer treatment type, with the lowest titers observed with immunotherapy plus chemotherapy and biological therapy.
“Long-term cellular memory could call into question the need for a third BNT162b2 booster dose,” the authors write.
One author disclosed financial ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
.jpg)
Cancer Survivors Have Lower Levels of Physical Activity 
Pharmacist-Led Med Review Improves Medication Quality in Older Patients With Cancer 
Mindfulness, Tai Chi May Benefit Cancer Survivors 
Nearly 3 in 4 Older Adults Express Interest in Vaccine to Prevent Dementia 
Lower Cognitive Functioning During 60s Linked to Subsequent Stroke Risk 
Polypharmacy of Prescription Medications Increased for U.S. Older Adults 
Nearly 1 in 10 Older Adults Used Cannabis in the Past Year 
Insomnia Linked to Increased Risk for Stroke, Odds of Admission 
.jpg)
